Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ERBB3 over exp PIK3CA H1047R |
| Therapy | Buparlisib |
| Indication/Tumor Type | breast cancer |
| Response Type | resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ERBB3 over exp PIK3CA H1047R | breast cancer | resistant | Buparlisib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, a breast cancer cell line xenograft model harboring ERBB3 (HER3) over expression and PIK3CA H1047R in brain metastases demonstrated resistance to treatment with Buparlisib (BKM120) (PMID: 28539475). | 28539475 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (28539475) | The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation. | Full reference... |